07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Teysuno tegafur/gimeracil/oteracil potassium: Phase III data

The double-blind, Japanese Phase III S-CUBE trial in 334 patients with advanced HCC whose disease progressed after treatment with or who were intolerant to Nexavar sorafenib showed that S-1 missed the primary endpoint of improving...
07:00 , Jun 3, 2013 |  BioCentury  |  Strategy

Taiho goes global

Taiho Pharmaceutical Co. Ltd. has embarked on a five-year plan to expand into Western markets using its late-stage chemotherapeutics as a beachhead for the company's pipeline of novel cancer candidates, including at least one that...
07:00 , Mar 11, 2013 |  BioCentury  |  Regulation

Dissecting Kadcyla

Two and a half years after FDA refused to file Genentech Inc. 's BLA for accelerated approval of Kadcyla ado-trastuzumab emtansine in metastatic breast cancer, the agency has granted full approval - and outlined its...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

Eniluracil: Completed Phase II enrollment

Adherex completed enrollment of 153 patients in the open-label, international Phase II AHX-03-202 trial comparing 40 mg oral eniluracil weekly for the first 3 weeks of a 4-week cycle plus oral 5-fluorouracil (5-FU) and oral...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Clinical News

Eniluracil: Interim Phase II data

Interim data from 122 evaluable patients who had previously been treated with an anthracycline and taxane in the open-label, international Phase II AHX-03-202 trial showed that once-weekly 40 mg oral eniluracil for the first 3...
07:00 , Aug 13, 2012 |  BioCentury  |  Emerging Company Profile

Inform Genomics: SNPing side effects

Inform Genomics Inc. is developing its OnPART test to predict which cancer patients are most likely to have chemotherapy side effects and allow doctors to treat the unwanted effects earlier or change the chemotherapy regimens...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

Eniluracil: Phase II started

Adherex began the open-label, international Phase II (AHX-03-202) trial in about 140 patients to compare 40 mg oral eniluracil weekly for the first 3 weeks of a 4-week cycle plus 5-fluorouracil (5-FU) and leucovorin vs....
07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

Adherex cancer news

Adherex reshuffled its management and said it will focus its remaining resources on the development of eniluracil , after restructuring and reducing headcount in April. Adherex hired shareholder Rosty Raykov as CEO and a director...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Eniluracil: Phase I/II suspended enrollment

Adherex closed enrollment in a dose-escalation, Asian Phase I/II trial after a reprioritization of its development programs. The trial, which had enrolled 9 patients, is evaluating oral eniluracil in combination with 5-fluorouracil. Adherex has exclusive...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Eniluracil: Phase I suspended enrollment

Adherex said it has temporarily suspended enrollment in a U.S. Phase I trial after a reprioritization of its development programs. The trial, which has enrolled 41 patients, is evaluating oral eniluracil in combination with 5-fluorouracil....